PEGylated Proteins Market-Global Industry Analysis and Forecast (2023-2029)


PEGylated Proteins Market is expected to reach US$ 2.50 Bn. at a CAGR of 10.45% during the forecast period 2029.

PEGylated Proteins Market Overview:

PEGylation is the process of attaching polyethylene glycol polymer chains to molecules, such as a medication, therapeutic protein, or vesicle, using covalent and non-covalent means. By changing the electrostatic binding, confirmation, and hydrophobicity of the molecule, PEGylation promotes medicine stability and solubility while lowering immunogenicity.PEGylated Proteins MarketTo know about the Research Methodology :- Request Free Sample Report

PEGylated Proteins Market Dynamics:

Rising prevalence of lifestyle diseases is the major factor driving the market growth.

The market is expected to grow due to the growing biologics industry, increased acceptance of protein-based medications over non-protein-based medications, and the increasing prevalence rate of lifestyle diseases. The rising frequency of chronic diseases such as cancer, kidney disease, and rheumatoid arthritis are driving the growth of the PEGylated protein therapies market. According to the Centres for Disease Control and Prevention's Chronic Kidney Disease in the United States, 2021 study, chronic kidney disease affects 15% of American adults, or 37 million people. These days, research into the creation of new therapies based on PEGylated proteins for the treatment of chronic renal disease is quite important. Protein-based medications are increasingly being preferred over non-protein-based medications because PEGylation improves protein circulation and half-life, therefore improving efficacy.

The market's growth is also fuelled by a wide range of applications and increased protein stability. In the forecast, top-selling biologics medications coming off-patent will generate growth prospects for the PEGylated proteins industry. On the other hand, rising PEGylation process costs and the patent expiration of certain medications are expected to hamper market growth.

The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

PEGylated Proteins Market Segment Analysis:

The Global PEGylated Proteins Market is segmented on the basis of Protein Type, Application and End-Users.

Based on Protein Type, the Colony Stimulating Factors segment is expected to grow at a higher CAGR of xx% during the forecast period. Colony-stimulating factors are compounds that speed up the creation of blood cells while also improving their functionality. They don't directly affect tumours, but they can have a function in activating blood cells, so they can help maintain a person's immune system throughout cancer treatment. The increasing incidence of cancer around the world, as well as the use of peptide treatment for cancer, is driving the segment's growth. According to Globocan, the global cancer incidence in 2022 is expected to be 19,292,789 cases, with almost 9,958,133 cancer-related deaths. Furthermore, increased patient and healthcare professional awareness of the negative consequences of existing cancer treatments, such as chemotherapy and radiation therapy, is a major reason for the growing interest in alternative medicines such as PEGylated peptide-based medications.

Based on Application, the Cancer segment is expected to hold a dominant market share xx% by 2029. The segment growth is attributed to the rising number of cancer-infected patients around the world. According to the World Health Organization, cancer is the second biggest cause of mortality, accounting for 9.6 million deaths worldwide in 2022, or one in every six deaths. Poly(ethylene glycol) (PEG)-based advanced drug delivery systems are a significant advancement in anti-cancer therapy. PEGylation can increase the retention period of treatments such as proteins, enzymes, tiny molecular medicines, liposomes, and nanoparticles by shielding them from numerous degrading mechanisms that occur inside a tissue or cell, hence improving their therapeutic efficacy.

PEGylated Proteins Market Regional Insights:

North America is expected to dominate the global market throughout the forecast period.

Throughout the projected period, North America is likely to dominate the global PEGylated protein market. The presence of prominent competitors, the high prevalence of chronic diseases in the region established healthcare infrastructure, and growing knowledge of modern treatment choices among the American population are some of the important factors driving the market's growth. Furthermore, the growing the elderly population and the increasing prevalence of chronic diseases are likely to contribute significantly to the market's growth. Growing demand for biologics medications such as erythropoietin, monoclonal antibodies, and interferon for treating chronic illnesses, as well as substantial government financing and grants for research activities are some of the major growth drivers in the region.

The report also helps in understanding Global PEGylated Proteins Market dynamics, structure by analyzing the market segments and project the Global PEGylated Proteins Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global PEGylated Proteins Market make the report investor’s guide.

PEGylated Proteins Market Scope: Inquire before buying






PEGylated Proteins Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 1.24 Bn.




Forecast Period 2023 to 2029 CAGR:
10.45%
Market Size in 2029:
US $ 2.50 Bn.




 Segments Covered:
by Protein Type
• Colony-stimulating Factors
• Interferons
• Erythropoietin
• Other Protein Types




by Application
• Cancer
• Autoimmune Disease
• Multiple Sclerosis
• Hemophilia
• Gastrointestinal Disorder




by End-Users
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes






PEGylated Proteins Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

PEGylated Proteins Market Key player

• Merck KGaA
• Thermo Fisher Scientific Inc.
• NOF America Corporation
• JenKem Technology USA
• Creative PEGWorks
• celares GmbH
• QUANTA BIODESIGN, LTD.
• Biomatrik Inc.
• IRIS BIOTECH GMBH
• Laysan Bio, Inc.
• Valley Proteins, Inc.
• Therapeutic Proteins International, LLC
• Enzon Pharamaceuticals, Inc
• Takeda Pharmaceuticals Company Limited
• F. Hoffmann-La Roche Ltd.
• Horizon Pharma plc.

Frequently Asked Questions:

1. Which region has the largest share in Global PEGylated Proteins Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global PEGylated Proteins Market?
Ans: The Global PEGylated Proteins Market is expected to grow at a CAGR of 10.45% during forecast period 2023-2029.

3. What is scope of the Global PEGylated Proteins market report?
Ans: Global PEGylated Proteins Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global PEGylated Proteins market?
Ans: The important key players in the Global PEGylated Proteins Market are – , Merck KGaA, Thermo Fisher Scientific Inc., NOF America Corporation, JenKem Technology USA, Creative PEGWorks, celares GmbH, QUANTA BIODESIGN, LTD., Biomatrik Inc., IRIS BIOTECH GMBH, Laysan Bio, Inc., Valley Proteins, Inc., Therapeutic Proteins International, LLC, Enzon Pharamaceuticals, Inc, Takeda Pharmaceuticals Company Limited, F. Hoffmann-La Roche Ltd., and Horizon Pharma plc.

5. What is the study period of this market?
Ans: The Global PEGylated Proteins Market is studied from 2022 to 2029. 




1. Preface
1.1. Market Definition and Key Research Objectives
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Calcium Channel Blocker Market Size, by Market Value (US$ Mn)
3.1. Global Market Segmentation
3.2. Global Market Segmentation Share Analysis, 2022
3.2.1. Global
3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
3.3. Geographical Snapshot of the Calcium Channel Blocker Market
3.4. Geographical Snapshot of the Calcium Channel Blocker Market, By Manufacturer share
4. Global Calcium Channel Blocker Market Overview, 2022-2029
4.1. Market Dynamics
4.1.1. Drivers
4.1.1.1. Global
4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.2. Restraints
4.1.2.1. Global
4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.3. Opportunities
4.1.3.1. Global
4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.4. Challenges
4.1.4.1. Global
4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa)
4.1.5. Industry Trends and Emerging Technologies
4.1.6. Porter Five Forces Analysis
4.1.6.1. The threat of New Entrants
4.1.6.2. Bargaining Power of Buyers/Consumers
4.1.6.3. Bargaining Power of Suppliers
4.1.6.4. The threat of Substitute Grades
4.1.6.5. The intensity of Competitive Rivalry
4.1.7. Value Chain Analysis
4.1.8. Technological Roadmap
4.1.9. Regulatory landscape
4.1.10. Impact of the Covid-19 Pandemic on the Global Calcium Channel Blocker Market
5. Supply Side and Demand Side Indicators
6. Global Calcium Channel Blocker Market Analysis and Forecast, 2022-2029
6.1. Global Calcium Channel Blocker Market Size & Y-o-Y Growth Analysis.
7. Global Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
7.1. Market Size (Value) Estimates & Forecast By Specimen, 2022-2029
7.1.1. Dihydropyridine
7.1.2. Benzothizepine
7.1.3. Phenylalkylamine
7.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
7.2.1. Hospital
7.2.2. Retail Pharmacies
7.2.3. Other
8. Global Calcium Channel Blocker Market Analysis and Forecasts, By Region
8.1. Market Size (Value) Estimates & Forecast By Region, 2022-2029
8.1.1. North America
8.1.2. Europe
8.1.3. Asia-Pacific
8.1.4. Middle East & Africa
8.1.5. South America
9. North America Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
9.1. Market Size (Value) Estimates & Forecast By Specimen, 2022-2029
9.1.1. Dihydropyridine
9.1.2. Benzothizepine
9.1.3. Phenylalkylamine
9.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
9.2.1. Hospital
9.2.2. Retail Pharmacies
9.2.3. Other
10. North America Calcium Channel Blocker Market Analysis and Forecasts, By Country
10.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
10.1.1. US
10.1.2. Canada
10.1.3. Mexico
11. U.S. Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
11.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
11.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
12. Canada Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
12.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
12.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
13. Mexico Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
13.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
13.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
14. Europe Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
14.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
14.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
15. Europe Calcium Channel Blocker Market Analysis and Forecasts, By Country
15.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
15.1.1. U.K
15.1.2. France
15.1.3. Germany
15.1.4. Italy
15.1.5. Spain
15.1.6. Sweden
15.1.7. CIS Countries
15.1.8. Rest of Europe
16. U.K Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
16.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
16.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
17. France Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
17.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
17.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
18. Germany Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
18.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
18.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
19. Italy Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
19.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
19.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
20. Spain Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
20.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
20.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
21. Sweden Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
21.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
21.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
22. CIS Countries Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
22.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
22.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
23. Rest of Europe Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
23.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
23.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
24. Asia Pacific Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
24.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
24.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
25. Asia Pacific Calcium Channel Blocker Market Analysis and Forecasts, by Country
25.1. Market Size (Value) Estimates & Forecast By Country, 2022-2029
25.1.1. China
25.1.2. India
25.1.3. Japan
25.1.4. South Korea
25.1.5. Australia
25.1.6. ASEAN
25.1.7. Rest of Asia Pacific
26. China Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
26.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
26.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
27. India Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
27.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
27.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
28. Japan Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
28.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
28.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
29. South Korea Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
29.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
29.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
30. Australia Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
30.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
30.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
31. ASEAN Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
31.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
31.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
32. Rest of Asia Pacific Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
32.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
32.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
33. Middle East Africa Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
33.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
33.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
34. Middle East Africa Calcium Channel Blocker Market Analysis and Forecasts, by Country
34.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
34.1.1. South Africa
34.1.2. GCC Countries
34.1.3. Egypt
34.1.4. Nigeria
34.1.5. Rest of ME&A
35. South Africa Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
35.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
35.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
36. GCC Countries Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
36.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
36.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
37. Egypt Textile Reinforced Concrete e-Market Analysis and Forecasts, 2022-2029
37.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
37.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
38. Nigeria Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
38.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
38.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
39. Rest of ME&A Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
39.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
39.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
40. South America Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
40.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
40.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
41. South America Calcium Channel Blocker Market Analysis and Forecasts, by Country
41.1. Market Size (Value) Estimates & Forecast by Country, 2022-2029
41.1.1. Brazil
41.1.2. Argentina
41.1.3. Rest of South America
42. Brazil Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
42.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
42.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
43. Argentina Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
43.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
43.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
44. Rest of South America Calcium Channel Blocker Market Analysis and Forecasts, 2022-2029
44.1. Market Size (Value) Estimates & Forecast By Drug Class, 2022-2029
44.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2022-2029
45. Competitive Landscape
45.1. Geographic Footprint of Major Players in the Global Calcium Channel Blocker Market
45.2. Competition Matrix
45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades, and R&D Investment
45.2.2. New Grade Launches and Grade Enhancements
45.2.3. Market Consolidation
45.2.3.1. M&A by Regions, Investment, and Verticals
45.2.3.2. M&A, Forward Integration and Backward
Integration
45.2.3.3. Partnership, Joint Ventures, and Strategic Alliances/ Sales Agreements
45.3. Company Profile: Key Players
45.3.1. Pfizer
45.3.1.1. Company Overview
45.3.1.2. Financial Overview
45.3.1.3. Geographic Footprint
45.3.1.4. Grade Portfolio
45.3.1.5. Business Strategy
45.3.1.6. Recent Development
45.3.2. Pfizer
45.3.3. Aventis
45.3.4. Searle
45.3.5. Bayer
45.3.6. AstraZeneca
45.3.7. Knoll Pharmaceuticals
45.3.8. Wyeth-Ayerst
45.3.9. AstraZeneca
45.3.10. Novartis
45.3.11. Sanofi.
45.3.12. ClearSynth
45.3.13. GlaxoSmithKline Plc.
45.3.14. AbMole Bioscience
45.3.15. Lupin Pharmaceuticals, Inc
46. Primary Key Insights
  • INQUIRE BEFORE BUYING